374 related articles for article (PubMed ID: 30112436)
1. Antibody-Drug Conjugates in Bladder Cancer.
Vlachostergios PJ; Jakubowski CD; Niaz MJ; Lee A; Thomas C; Hackett AL; Patel P; Rashid N; Tagawa ST
Bladder Cancer; 2018 Jul; 4(3):247-259. PubMed ID: 30112436
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates for urothelial carcinoma.
Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Nagayama A; Ellisen LW; Chabner B; Bardia A
Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
[TBL] [Abstract][Full Text] [Related]
7. The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.
Hanna KS; Larson S; Nguyen J; Boudreau J; Bulin J; Rolf M
Am J Health Syst Pharm; 2022 Apr; 79(8):629-635. PubMed ID: 34864835
[TBL] [Abstract][Full Text] [Related]
8. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
Shih CH; Lin YH; Luo HL; Sung WW
Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
[TBL] [Abstract][Full Text] [Related]
11. Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
Alameddine R; Mallea P; Shahab F; Zakharia Y
Curr Treat Options Oncol; 2023 Sep; 24(9):1167-1182. PubMed ID: 37403009
[TBL] [Abstract][Full Text] [Related]
12. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
[TBL] [Abstract][Full Text] [Related]
14. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
Goldenberg DM; Sharkey RM
MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
[TBL] [Abstract][Full Text] [Related]
17. [ANTIBODY-DRUG CONJUGATES - A NOVEL APPROACH FOR THE TREATMENT OF METASTATIC UROTHELIAL CARCINOMA].
Sternschuss M; Sarfaty M
Harefuah; 2022 Jan; 161(1):49-54. PubMed ID: 35077061
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan.
Dong W; Shi J; Yuan T; Qi B; Yu J; Dai J; He L
Eur J Med Chem; 2019 Apr; 167():583-593. PubMed ID: 30822636
[TBL] [Abstract][Full Text] [Related]
19. Sacituzumab govitecan: an antibody-drug conjugate.
Sahota S; Vahdat LT
Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
[TBL] [Abstract][Full Text] [Related]
20. Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon.
Khadela A; Soni S; Shah AC; Pandya AJ; Megha K; Kothari N; Cb A
Med Oncol; 2022 Dec; 40(1):25. PubMed ID: 36456774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
